[논문]Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers

Noh, Yook-Hwan; Lim, Hyeong-Seok; Kim, Mi Jo; Kim, Yo Han; Choi, Hee Youn; Sung, Hye Ryoung; Jin, Seok-Joon; Lim, Jonglae; Bae, Kyun-Seop

doi:10.1016/j.clinthera.2012.05.010

Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers

Clinical therapeutics, v.34 no.7, 2012년, pp.1625 - 1635

Noh, Yook-Hwan (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Lim, Hyeong-Seok (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Kim, Mi Jo (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Kim, Yo Han (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Choi, Hee Youn (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Sung, Hye Ryoung (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Jin, Seok-Joon (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea) , Lim, Jonglae (Technical Research Center, CKD Research Institute, Yongin, Korea) , Bae, Kyun-Seop (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea)

Abstract ▼ AI-Helper

AbstractBackgroundTelmisartan belongs to a class of orally active angiotensin II receptor blockers (ARBs), and S-amlodipine is an enantiomer of amlodipine. Amlodipine is a racemic mixture and the calcium channel blocking (CCB) effect is confined to S-amlodipine, whereas R-amlodipine has a 1000-fold lower activity and no racemization occurs in vivo in human plasma. Combination therapy of ARBs with CCBs provides advantages for blood pressure control and vascular protection over monotherapy.ObjectiveTo investigate the effects of coadministration of telmisartan and S-amlodipine on the steady-state pharmacokinetic properties of each drug as a drug–drug interaction study required before developing the fixed-dose combination agent.MethodsThis study comprised 2 separate parts, A and B; each was a multiple-dose, open-label, 2-sequence, 2-period, crossover study in healthy male Korean volunteers. In part A, volunteers were administered 80 mg of telmisartan, either alone or with 5 mg of S-amlodipine. In part B, volunteers were administered 5 mg of S-amlodipine, either alone or with 80 mg of telmisartan. Blood samples were taken on days 9 and 37, following the final dose of each treatment, and at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours after administration in part A, and were taken at 0 (predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, and 24 hours after administration in part B. Plasma concentrations were determined using LC-MS/MS. The pharmacokinetic properties of each drug after coadministration of telmisartan and S-amlodipine were compared with those of each drug administered alone. Tolerability was assessed using measurements of vital signs, clinical chemistry tests, and interviews.ResultsFifty-six volunteers were enrolled (32 in part A and 24 in part B), and all completed except 4 volunteers (3 withdrawn in part A and 1 withdrawn in part B). The geometric mean ratios (GMRs) (90% CI) for the Cmax,ss and AUCτ,ss of telmisartan (with or without S-amlodipine) were 1.039 (0.881–1.226) and 1.003 (0.926–1.087), respectively. The GMRs (90% CI) for Cmax,ss and AUCτ,ss of S-amlodipine (with or without telmisartan) were 0.973 (0.880–1.076) and 0.987 (0.897–1.085). Total 11 adverse events (AEs) were reported in 7 volunteers (21.9%) in part A. A total of 9 AEs were reported in 6 volunteers (25.0%) in part B. Statistical analysis confirmed that the 90% CIs for these pharmacokinetic parameters were within the commonly accepted bioequivalence range of 0.8 to 1.25, indicating that the extent of bioavailability of S-amlodipine was not affected by telmisartan. The intensity of all AEs was considered to be mild, and there were no significant differences in the prevalences of AEs between the 2 formulations.ConclusionsFollowing multiple-dose coadministration of high doses of telmisartan and S-amlodipine, the steady-state pharmacokinetic properties of telmisartan were not significantly affected, and telmisartan had no significant effect on the pharmacokinetic properties of S-amlodipine at steady state in these selected groups of healthy volunteers. Both formulations were generally well-tolerated. ClinicalTrials.gov identifiers: NCT01356017 and NCT01356043.

주제어

참고문헌 (39)

J Hypertens Benndorf 26 854 2008 10.1097/HJH.0b013e3282f76481 Pleiotropic effects of telmisartan: still more to come?

상세보기
Drugs Battershill 66 51 2006 10.2165/00003495-200666010-00004 Telmisartan: a review of its use in the management of hypertension

상세보기
J Hypertens Karlberg 17 293 1999 10.1097/00004872-199917020-00015 Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension

상세보기
Am J Ther Neutel 6 161 1999 10.1097/00045391-199905000-00007 Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension

상세보기
Dipiro 2011 Pharmacotherapy-A Pathophysiologic Approach
N Engl J Med Cooper 354 2443 2006 10.1056/NEJMoa055202 Major congenital malformations after first-trimester exposure to ACE inhibitors

상세보기
Ter Arkh Chazova 75 89 2003 Telmisartan (micardis)-an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?
Drugs Haria 50 560 1995 10.2165/00003495-199550030-00009 Amlodipine

상세보기
Lancet Tucker 355 1085 2000 10.1016/S0140-6736(00)02047-X Chiral switches

상세보기
J Med Chem Goldmann 35 3341 1992 10.1021/jm00096a005 Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction

상세보기
J Cardiovasc Pharmacol Zhang 39 208 2002 10.1097/00005344-200202000-00007 Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine

상세보기
J Biochem Biophys Methods Rentsch 54 1 2002 10.1016/S0165-022X(02)00124-0 The importance of stereoselective determination of drugs in the clinical laboratory

상세보기
J Chromatogr B Biomed Sci Appl Luksa 703 185 1997 10.1016/S0378-4347(97)00394-0 Pharmacokinetic behaviour of R-(+)- and S-(−)-amlodipine after single enantiomer administration

상세보기
J Assoc Phys India Adik-Pathak 52 187 2004 Chiral molecules in hypertension: focus on S-amlodipine
J Biochem Biophys Methods Streel 54 357 2002 10.1016/S0165-022X(02)00133-1 Enantiomeric determination of amlodipine in human plasma by liquid chromatography coupled to tandem mass spectrometry

상세보기
J Clin Hypertens (Greenwich) Cushman 4 393 2002 10.1111/j.1524-6175.2002.02045.x Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

상세보기
JAMA Chobanian 289 2560 2003 10.1001/jama.289.19.2560 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

상세보기
Am J Cardiovasc Drugs Chrysant 10 315 2010 10.2165/11538850-000000000-00000 The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies

상세보기
Clin Drug Invest da Silva 30 625 2010 10.2165/11538440-000000000-00000 Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan

상세보기
Hypertens Res Ishimitsu 32 962 2009 10.1038/hr.2009.133 Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension

상세보기
J Gen Intern Med Pan 23 611 2008 10.1007/s11606-008-0544-x Impact of fixed-dose combination drugs on adherence to prescription medications

상세보기
Postgrad Med Guthrie 123 58 2011 10.3810/pgm.2011.11.2495 Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension

상세보기
Expert Opin Drug Metab Toxicol Deppe 6 863 2010 10.1517/17425255.2010.494597 Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties

상세보기
Clin Ther Kim 32 193 2010 10.1016/j.clinthera.2010.01.017

상세보기
Guidance for Industry, Bioanalytical Method Validation 2003
J Chromatogr B Li 828 126 2005 10.1016/j.jchromb.2005.09.021 Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry

상세보기
Clin Ther Park 28 1837 2006 10.1016/j.clinthera.2006.11.008 Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study

상세보기
Rowland 2011 Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications
Gabrielsson 2007 Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications
Chow 2009 Design and Analysis of Bioavailability and Bioequivalence Studies
Int J Clin Pharmacol Ther Toxicol Diletti 30 Suppl 1 S51 1992 Sample size determination for bioequivalence assessment by means of confidence intervals
Kutner 2005 Applied Linear Statistical Models
Crit Care Nurs Clin North Am Kroon 18 53 2006 10.1016/j.ccell.2005.11.007 Drug interactions and smoking: raising awareness for acute and critical care providers

상세보기
Drug Saf Michel 27 335 2004 10.2165/00002018-200427050-00005 Safety of telmisartan in patients with arterial hypertension: an open-label observational study

상세보기
J Cardiovasc Pharmacol Endersby 17 Suppl 4 S45 1991 10.1097/00005344-199117041-00010 Safety profile of lacidipine: a review of clinical data

상세보기
J Clin Pharmacol Stangier 40 1347 2000 10.1177/009127000004001206 Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers

상세보기
Fundamental Clin Pharmacol Bolbrinker 23 767 2009 10.1111/j.1472-8206.2009.00720.x Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects

상세보기
Clin Ther Philipp 29 563 2007 10.1016/j.clinthera.2007.03.018

상세보기
J Clin Hypertens (Greenwich) Littlejohn 11 207 2009 10.1111/j.1751-7176.2009.00098.x Results of treatment with telmisartan-amlodipine in hypertensive patients

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers

Abstract ▼ AI-Helper

주제어

참고문헌 (39)

이 논문을 인용한 문헌

관련 콘텐츠

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트